FACULTY
Joseph K. Han, MD, FARS, FAAOA
Professor of Otolaryngology
Vice Chair of Clinical Affairs and Administration
Chief, Division of Rhinology and Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, Virginia
Dr. Joseph Han is Chief of the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, as well as Chief of the Division of Allergy. Dr. Han holds a Bachelor of Science degree from the University of Washington, earned his MD from the Medical College of Pennsylvania, and completed an otolaryngologyhead and neck surgery residency at the Medical College of Wisconsin and a fellowship in rhinology at Oregon Health Sciences University.
Dr. Han has received numerous awards, including Best Doctors of America and Top Doctors by US News & Report. He is a national and international leader in rhinology, allergy, and endoscopic skull base surgery. He was president of the American Rhinologic Society (ARS), Virginia Society of Otolaryngology, Tidewater Otolaryngology & Ophthalmology Society, and Korean American Otolaryngology Society and chair of the Rhinology and Paranasal Sinus Committee of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS). He is Chair of the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee for the American Academy of Allergy, Asthma & Immunology.
Dr. Han was an associate editor for 2 scientific journals and is currently on the editorial board of the International Forum of Allergy & Rhinology. He is a guest examiner for the American Board of Otolaryngology – Head and Neck Surgery. Dr. Han is Editor of Practical Medical and Surgical Management of Chronic Rhinosinusitis and a Section Editor of Ballenger’s Otolaryngology: Head and Neck Surgery. He was involved in the AAO-HNS Guidelines Task Force. He has more than 100 scientific publications, 175 national and international scientific presentations, and 150 guest lectureships.
Dr. Han is very active in both basic science research and clinical research studies. His thesis was on subclassification of chronic rhinosinusitis (CRS), endotyping and phenotyping CRS. He has been awarded National Institutes of Health (NIH) funding for the study of chronic sinusitis and has been lead investigator for several multinational, multi-institutional, prospective clinical trials on chronic sinusitis and nasal polyposis, including the use of biologics for nasal polyps. His clinical interests include allergies, nasal obstruction, sinusitis, cerebrospinal fluid leakage, and nasal/skull base tumors. He is one of the pioneers of endoscopic skull base surgery.
Flavia Hoyte, MD
Professor of Medicine, Division of Allergy and Immunology Director, Allergy and Clinical Immunology
Fellowship Program
National Jewish Health/University of Colorado Denver, Colorado
Flavia Hoyte, MD, is a Professor of Medicine in the Division of Allergy and Immunology at National Jewish Health, with a joint appointment at the University of Colorado. She specializes in adult allergic and immunologic conditions, asthma, and pulmonary conditions. Dr. Hoyte graduated from Princeton University with a degree in molecular biology and received her medical degree from New York University School of Medicine. She subsequently completed a combined residency in internal medicine and pediatrics at the University of Chicago Hospitals and a fellowship in allergy and immunology at National Jewish Health and the University of Colorado. Following graduation, she remained on faculty and currently serves as clinician, educator of residents and fellows, and clinical researcher in several investigator-initiated studies and company-sponsored trials. Her research interests include novel diagnostic and therapeutic interventions for chronic sinusitis and asthma. She has served as program director for the National Jewish/University of Colorado Adult Allergy and Immunology Fellowship Training Program since 2015. Dr. Hoyte is a member of the Colorado Allergy and Asthma Society (CAAS), the Western Society of Allergy, Asthma and Immunology (WSAAI), and the American Academy of Allergy, Asthma, and Immunology (AAAAI) and is a fellow of the American College of Allergy, Asthma, and Immunology (ACAAI).
Nizar N. Jarjour, MD, ATSF
Ovid O. Meyer Professor of Medicine Department of Medicine
University of Wisconsin School of Medicine and Public Health Madison, Wisconsin
Dr. Nizar Jarjour is the chief of the Division of Allergy, Pulmonary and Critical Care Medicine and Ovid O. Meyer Professor of Medicine in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. He is a past president of the University of Wisconsin Medical Foundation (UWMF) and the Wisconsin Thoracic Society. He has served on various study sections at the National Institute of Health and as a member of the American Board of Internal Medicine - Pulmonary Specialty Board and as a member of the FDA Allergy and Pulmonary Drug Advisory Committee. He is a member of the American Thoracic Society and the European Thoracic Society.
Dr. Jarjour’s clinical activities include staffing the outpatient pulmonary clinic and directing the pulmonary diagnostics laboratory.
Dr. Jarjour’s research program includes mechanisms of allergic inflammation, the role of eosinophil in airway disease, the pathogenesis of viral-induced asthma exacerbations, etiology and characteristics of severe asthma, and mechanisms of action of anti-asthma medication, airway remodeling and clinical aspects of asthma. He has served as a principal investigator for several multicenter NIH-funded collaborative grants, among them a recent grant focused on mechanisms of severe asthma and another grant examining precision therapies in severe asthma.
He has also led research studies on the mechanism of allergic inflammationdriven airway remodeling and interdisciplinary studies on the systemic effects of airway inflammation, especially the cardiovascular and brain changes related to airway inflammation. He has contributed to 250 scientific publications with nearly 2000 scientific citations per year.
PROGRAM DESCRIPTION
Join us for dinner and a dynamic Mechanisms to Medicine symposium featuring expert panelists Drs. Joseph Han, Flavia Hoyte, and Nizar Jarjour as they examine evolving management approaches for epithelial cytokine–driven inflammatory diseases of the upper and lower airways. This program brings together multidisciplinary perspectives from pulmonology, allergy and immunology, and otorhinolaryngology to explore shared underlying disease mechanisms in asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
The engaging faculty panel will guide participants through an examination of epithelial cytokine signaling in airway diseases and practical therapeutic decision-making involving new and emerging biologic therapies that target these shared upstream mechanisms. Through a focused Whiteboard animation, case-based checkpoints, and interactive faculty dialogue, learners will examine how epithelial alarmins such as thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33) drive inflammation, airway dysfunction, and disease persistence.
Attendees will also learn about the latest clinical evidence for newer and emerging biologic therapies that target upstream epithelial cytokine signaling and discuss how to incorporate these novel therapies into mechanism-based treatment strategies, with an emphasis on optimizing disease control, reducing oral corticosteroid use, and improving outcomes across the unified airway.
TARGET AUDIENCE
This educational activity has been designed to educate pulmonologists, clinical immunologists/allergists, and ear, nose, and throat [ENT] specialists who manage patients with epithelial-driven inflammatory airway diseases.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants will be better prepared to:
• Explain the pathogenesis of epithelial-driven inflammatory airway diseases, including implications for the treatment of asthma, CRSwNP, and COPD
• Discuss the clinical profiles and evidence for biologic therapies that target epithelial cytokines in the treatment of epithelial-driven inflammatory airway diseases
• Incorporate biologic medications into therapeutic regimens for epithelial-driven inflammatory airway diseases to address underlying pathophysiologic processes, improve disease control, and reduce oral corticosteroid use
PROGRAM AGENDA
6:30 pm Registration and Dinner
7:00 pm Preactivity Questionnaire and Faculty Introductions
7:10 pm Early Signaling in Inflammatory Airway Diseases
7:25 pm Advances in the Management of Severe Asthma
7:40 pm Applying a Mechanism-Based Framework to Inflammatory Diseases of the Upper Airways
7:55 pm A New Era in COPD Management: Here Come the Biologics
8:15 pm Key Takeaways, Recap, Postactivity Questionnaire, and Q&A Session
PHYSICIAN ACCREDITATION STATEMENT
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Integritas Communications designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation.
DISCLOSURES OF CONFLICTS OF INTEREST
Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in
accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Joseph Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi
Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Sanofi, Teva Pharmaceutical Industries Ltd.; Fees for Non-CE Services
Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc; Stock Shareholder: Amgen
Nizar Jarjour, MD: Consulting Fees: AstraZeneca plc, Chiesi, General Medicines, and GSK plc
The Integritas planners and managers have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this activity.
CONTACT INFORMATION
For information about this program, please contact us at info@exchangecme.com.
CLINICAL PRACTICE GUIDELINES
» Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma, 2026. https://ginasthma.org/2026-gina-strategy-report/
» EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Fokkens WJ, et al. Rhinology. 2023;61(3):194-202. https://www.rhinologyjournal.com/download.php?id=3069
» Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
Global Initiative for Chronic Obstructive Lung Disease, 2026. https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.38Dec2025_WMV2.pdf
» Patient-Reported Outcomes Measures (PROM) Sino-Nasal Outcome Test-22 (SNOT-22) https://www.researchgate.net/figure/SNOT-22-Questionnaire_fig1_246548471
» St. George’s Respiratory Questionnaire (SGRQ) https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id=phd003584.2
» Asthma Quality of Life Questionnaire (AQLQ) http://www.qoltech.co.uk/index.htm
SUGGESTED READING
» The unified airway hypothesis: evidence from specific intervention with anti-IL-5 biologic therapy.
Bachert C, et al. J Allergy Clin Immunol Pract. 2023;11(9):2630-2641. https://www.jaci-inpractice.org/article/S2213-2198(23)00547-0/fulltext
» Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response.
Duchesne M, et al. Front Immunol. 2022;13:975914. https://www.frontiersin.org/journals/immunology/articles/10.3389/ fimmu.2022.975914/full
» Type 2 inflammation in asthma and other airway diseases.
Maspero J, et al. ERJ Open Res. 2022;8(3):00576-2021. https://pmc.ncbi.nlm.nih.gov/articles/pmid/35923421/
» The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.
Yang C, et al. Front Allergy. 2025;6:1599797.
https://www.frontiersin.org/journals/allergy/articles/10.3389/ falgy.2025.1599797/pdf
» T2 biologics for chronic obstructive pulmonary disease.
Yousuf A, et al. J Allergy Clin Immunol Pract. 2019;7(5):1405-1416. https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(19)30106-0
» FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in earlyonset asthma.
Corren J, et al. ERJ Open Res. 2026;12(1):00183-2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12926823/pdf/00183-2025.pdf
» Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.
Kelsen SG, et al. J Allergy Clin Immunol. 2021;148(3):790-798. https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(21)00609-6
» Efficacy and safety of itepekimab in patients with moderate-tosevere asthma.
Wechsler ME, et al. N Engl J Med. 2021;385(18):1656-1668. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024257
» Tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809. https://www.nejm.org/doi/full/10.1056/NEJMoa2034975
» Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps.
Lipworth BJ, et al. N Engl J Med. 2025;392(12):1178-1188. https://www.nejm.org/doi/abs/10.1056/NEJMoa2414482
» A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
Singh D, et al. Eur Respir J. 2025;66(1):2402231. https://pmc.ncbi.nlm.nih.gov/articles/PMC12256803/pdf/ERJ-02231-2024.pdf
» Safety and efficacy of itepekimab in patients with moderate-tosevere COPD: a genetic association study and randomised, doubleblind, phase 2a trial.
Rabe KF, et al. Lancet Respir Med. 2021;9(11):1288-1298. https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(21)00167-3
» Consensus summary on the definition of asthma remission.
Katial RK, et al. J Allergy Clin Immunol. 2025;156(3 suppl):S20-S24. https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(25)00746-8
» Consensus criteria for chronic rhinosinusitis disease control: an international Delphi study.
Sedaghat AR, et al. Rhinology. 2023;61(6):519-530. https://www.rhinologyjournal.com/Abstract.php?id=3118
» ATS 2026 International Conference. Online program. https://ats2026.d365.events/education/program
PATIENT ADVOCACY ORGANIZATIONS AND RESOURCES
» Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research. http://www.aafa.org/page/asthma.aspx
» American Academy of Allergy, Asthma, & Immunology (AAAAI)
The AAAAI is the leading membership organization of more than 7100 allergists/immunologists and patients’ trusted resource for allergies, asthma and immune deficiency disorders. https://www.aaaai.org/
» American College of Allergy, Asthma, & Immunology (ACAAI)
The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research. https://acaai.org/asthma
» American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/asthma/
» American Thoracic Society (ATS)
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders. https://www.thoracic.org/patients/patient-resources/
» Chest Foundation
The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health. foundation.chestnet.org/patient-education-resources/asthma/
» COPD Foundation
The COPD Foundation’s mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. https://www.copdfoundation.org/
NOTES
NOTES
NOTES
A Focus on Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome
ExchangeCME.com/TacklingEGPAHES Severe Asthma Bridge
Improving Clinical Outcomes For Patients with Severe or Uncontrolled Asthma
ExchangeCME.com/SABridgeEnduring
Changing the EGPA Trajectory With Early Diagnosis and Biologic Therapy
ExchangeCME.com/EGPAChicago
ExchangeCME.com is the fastest-growing digital platform for accredited CME/CE and MOC programming. Join the movement of thousands of health care professionals and make sure you stay up to date on best practices to manage your patients!
Free accredited online activities with immediate access to your certificates
Live in-person and online events
Clinical Resource Centers on various therapeutic areas
Live streaming of symposia at major medical conferences
Tailored e-newsletters based on your interest
